Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Robert F. Williamson III acquired 25,266 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were acquired at an average cost of 0.64 per share, for a total transaction of 16,170.24. Following the purchase, the director now directly owns 211,555 shares of the company’s stock, valued at 135,395.20. The purchase was disclosed in a legal filing with the SEC, which is available at this link.
Perspective Therapeutics Stock Performance
Shares of Perspective Therapeutics stock opened at 0.81 on Thursday. The company has a market cap of $227.23 million, a P/E ratio of -8.10 and a beta of 1.62. Perspective Therapeutics, Inc. has a twelve month low of 0.21 and a twelve month high of 0.85. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.55 and a current ratio of 2.67.
Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last issued its quarterly earnings data on Tuesday, November 14th. The company reported -0.04 earnings per share for the quarter, meeting analysts’ consensus estimates of -0.04. The company had revenue of 2.19 million for the quarter, compared to the consensus estimate of 2.20 million. Perspective Therapeutics had a negative net margin of 302.70% and a negative return on equity of 22.80%. Equities analysts expect that Perspective Therapeutics, Inc. will post -0.14 EPS for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analyst Weigh In
CATX has been the topic of several research reports. B. Riley initiated coverage on shares of Perspective Therapeutics in a research note on Friday, January 26th. They set a “buy” rating and a $1.20 price objective on the stock. Jonestrading started coverage on shares of Perspective Therapeutics in a research note on Wednesday, November 15th. They issued a “buy” rating and a $1.40 target price on the stock.
About Perspective Therapeutics
Perspective Therapeutics, Inc, together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers.
- Five stocks we like better than Perspective Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- What is a bear market rally? Examples and how they work
- How to Invest in the FAANG Stocks
- 7 best bear market ETFs to battle a decline
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- 10 best sugar stocks to buy now
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.